Diseases caused by the new coronavirus
Conditions
Interventions
Diabetes group:Inactivated new coronavirus vaccine (Vero cells)
Hypertension group:Inactivated new coronavirus vaccine (Vero cells)
Healthy control group:Inactivated new coronavirus vaccine (Vero cells)
Sponsors
Guizhou Center for Disease Control and Prevention
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. People aged >= 60 years with full capacity for civil conduct; 2. Body temperature < 37.3? was confirmed by clinical examination before entering this study; 3. Able and willing to complete the entire research plan during the follow-up period; 4. I have the ability to understand the study procedure, sign the informed consent voluntarily with informed consent, and comply with the requirements of the clinical study protocol; 5. Inclusion criteria for patients with hypertension/diabetes: they must be diagnosed with hypertension and/or diabetes by a medical institution of grade I or above.
Exclusion criteria
Exclusion criteria: 1. Recipients have a history of COVID-19 infection or have tested positive for NUCLEIC acid; 2. Subjects have a history of COVID-19 vaccination; 3. Known to be allergic to any ingredients contained in the product (including excipients); 4. Injection of non-specific immunoglobulin within 1 month before enrollment; 5. Have received live attenuated vaccine within 1 month before inoculation and other vaccines within 14 days before inoculation; 6. Patients who have experienced severe allergic reactions to vaccines (such as acute allergic reactions, urticaria, angioneurotic edema, dyspnea, etc.); 7. Persons with uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome; 8. Serious respiratory diseases, serious liver and kidney diseases, malignant tumors, various acute diseases or acute episodes of chronic diseases; 9. Have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; 10. A clearly diagnosed history of thrombocytopenia or other clotting disorders may contraindicate subcutaneous injection; 11. During the acute complications of diabetes (ketoacidosis, hyperosmolar state, lactic acidosis, etc.); Or the above complications have been cured less than 2 weeks; 12. Other patients whose physical conditions were deemed unsuitable for clinical study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive rate of neutralizing antibody and GMT level of neutralizing antibody in novel Coronavirus;Occurrence of adverse events within 3 months after full immunization; | — |
Countries
China
Contacts
Public ContactZhang Ruizhi
Guizhou Center for Disease Control and Prevention
Outcome results
None listed